对有症状的初级保健患者进行粪便免疫化学检验:诊断准确性研究

IF 1.8 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Alex J. Ball, Meghna Ray, Arif Manji, Imran Aziz, Ravishankar B. Sargur, Matthew Kurien
{"title":"对有症状的初级保健患者进行粪便免疫化学检验:诊断准确性研究","authors":"Alex J. Ball,&nbsp;Meghna Ray,&nbsp;Arif Manji,&nbsp;Imran Aziz,&nbsp;Ravishankar B. Sargur,&nbsp;Matthew Kurien","doi":"10.1155/2024/4849620","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Aim:</b> The faecal immunochemical test (FIT) is now widely used in English primary care to triage people who exhibit signs or symptoms of colorectal cancer (CRC). National guidelines for FIT implementation were based on data that acknowledged limitations. This study examines FIT accuracy in primary care patients with low- and high-risk symptoms of CRC.</p>\n <p><b>Methods:</b> This study describes a retrospective cohort study in South Yorkshire, UK (<i>n</i> = 2029). Consecutive symptomatic adult patients in primary care undergoing a FIT between 01/04/2021 and 30/04/2021 were assessed. A threshold &gt; 10 μg Hb/g was defined as a positive FIT result. Lower gastrointestinal tract (LGI) investigations were the reference standard. Follow-up over 24 months was used to identify serious colorectal diseases (CRC, high-risk polyps and inflammatory bowel disease [IBD]).</p>\n <p><b>Results:</b> Five hundred and fifteen (25.4%) patients had a positive FIT. The CRC prevalence was 1.2% (24/2029). Nineteen (79.1%) of the 24 CRC cases had NG12 symptoms, with two (8.3%) having a negative FIT. For CRC detection, FIT showed 91.7% sensitivity (95% CI: 71.5%–98.5%), 75.4% specificity (95% CI: 73.4%–77.2%), 4.3% positive predictive value (PPV) (95% CI: 2.8%–6.5%) and 99.9% negative predictive value (NPV) (95% CI: 99.5%–99.97%). Combining CRC, high-risk polyps and IBD increased PPV and specificity but decreased sensitivity and NPV.</p>\n <p><b>Conclusions:</b> In primary care, FIT safely triages patients having at-risk CRC risk symptoms. Negative FIT results indicate a low likelihood of CRC and supports safety-netting interventions.</p>\n </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":"2024 1","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4849620","citationCount":"0","resultStr":"{\"title\":\"Faecal Immunochemical Testing in Symptomatic Primary Care Patients: A Diagnostic Accuracy Study\",\"authors\":\"Alex J. Ball,&nbsp;Meghna Ray,&nbsp;Arif Manji,&nbsp;Imran Aziz,&nbsp;Ravishankar B. Sargur,&nbsp;Matthew Kurien\",\"doi\":\"10.1155/2024/4849620\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><b>Aim:</b> The faecal immunochemical test (FIT) is now widely used in English primary care to triage people who exhibit signs or symptoms of colorectal cancer (CRC). National guidelines for FIT implementation were based on data that acknowledged limitations. This study examines FIT accuracy in primary care patients with low- and high-risk symptoms of CRC.</p>\\n <p><b>Methods:</b> This study describes a retrospective cohort study in South Yorkshire, UK (<i>n</i> = 2029). Consecutive symptomatic adult patients in primary care undergoing a FIT between 01/04/2021 and 30/04/2021 were assessed. A threshold &gt; 10 μg Hb/g was defined as a positive FIT result. Lower gastrointestinal tract (LGI) investigations were the reference standard. Follow-up over 24 months was used to identify serious colorectal diseases (CRC, high-risk polyps and inflammatory bowel disease [IBD]).</p>\\n <p><b>Results:</b> Five hundred and fifteen (25.4%) patients had a positive FIT. The CRC prevalence was 1.2% (24/2029). Nineteen (79.1%) of the 24 CRC cases had NG12 symptoms, with two (8.3%) having a negative FIT. For CRC detection, FIT showed 91.7% sensitivity (95% CI: 71.5%–98.5%), 75.4% specificity (95% CI: 73.4%–77.2%), 4.3% positive predictive value (PPV) (95% CI: 2.8%–6.5%) and 99.9% negative predictive value (NPV) (95% CI: 99.5%–99.97%). Combining CRC, high-risk polyps and IBD increased PPV and specificity but decreased sensitivity and NPV.</p>\\n <p><b>Conclusions:</b> In primary care, FIT safely triages patients having at-risk CRC risk symptoms. Negative FIT results indicate a low likelihood of CRC and supports safety-netting interventions.</p>\\n </div>\",\"PeriodicalId\":11953,\"journal\":{\"name\":\"European Journal of Cancer Care\",\"volume\":\"2024 1\",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4849620\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2024/4849620\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Care","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/4849620","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

目的:粪便免疫化学检验 (FIT) 现已广泛应用于英国初级医疗机构,以分流出现结直肠癌 (CRC) 症状或体征的患者。实施 FIT 的国家指导方针基于承认局限性的数据。本研究探讨了 FIT 在初级保健中对有低风险和高风险 CRC 症状的患者的准确性。 方法:本研究描述了在英国南约克郡进行的一项回顾性队列研究(n = 2029)。对 2021 年 4 月 1 日至 2021 年 4 月 30 日期间接受 FIT 检查的连续有症状的初级保健成年患者进行了评估。阈值 > 10 μg Hb/g 被定义为 FIT 阳性结果。下消化道(LGI)检查是参考标准。24 个月的随访用于确定严重的结直肠疾病(CRC、高危息肉和炎症性肠病 [IBD])。 研究结果有 515 名(25.4%)患者的 FIT 呈阳性。CRC 患病率为 1.2%(24/2029)。在 24 例 CRC 中,19 例(79.1%)有 NG12 症状,2 例(8.3%)FIT 为阴性。对于 CRC 检测,FIT 的灵敏度为 91.7%(95% CI:71.5%-98.5%),特异度为 75.4%(95% CI:73.4%-77.2%),阳性预测值为 4.3%(95% CI:2.8%-6.5%),阴性预测值为 99.9%(95% CI:99.5%-99.97%)。将 CRC、高危息肉和 IBD 合并可提高 PPV 和特异性,但会降低敏感性和 NPV。 结论在初级保健中,FIT 能安全地分流有高危 CRC 危险症状的患者。FIT 阴性结果表明患上 CRC 的可能性较低,有助于采取安全网干预措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Faecal Immunochemical Testing in Symptomatic Primary Care Patients: A Diagnostic Accuracy Study

Faecal Immunochemical Testing in Symptomatic Primary Care Patients: A Diagnostic Accuracy Study

Aim: The faecal immunochemical test (FIT) is now widely used in English primary care to triage people who exhibit signs or symptoms of colorectal cancer (CRC). National guidelines for FIT implementation were based on data that acknowledged limitations. This study examines FIT accuracy in primary care patients with low- and high-risk symptoms of CRC.

Methods: This study describes a retrospective cohort study in South Yorkshire, UK (n = 2029). Consecutive symptomatic adult patients in primary care undergoing a FIT between 01/04/2021 and 30/04/2021 were assessed. A threshold > 10 μg Hb/g was defined as a positive FIT result. Lower gastrointestinal tract (LGI) investigations were the reference standard. Follow-up over 24 months was used to identify serious colorectal diseases (CRC, high-risk polyps and inflammatory bowel disease [IBD]).

Results: Five hundred and fifteen (25.4%) patients had a positive FIT. The CRC prevalence was 1.2% (24/2029). Nineteen (79.1%) of the 24 CRC cases had NG12 symptoms, with two (8.3%) having a negative FIT. For CRC detection, FIT showed 91.7% sensitivity (95% CI: 71.5%–98.5%), 75.4% specificity (95% CI: 73.4%–77.2%), 4.3% positive predictive value (PPV) (95% CI: 2.8%–6.5%) and 99.9% negative predictive value (NPV) (95% CI: 99.5%–99.97%). Combining CRC, high-risk polyps and IBD increased PPV and specificity but decreased sensitivity and NPV.

Conclusions: In primary care, FIT safely triages patients having at-risk CRC risk symptoms. Negative FIT results indicate a low likelihood of CRC and supports safety-netting interventions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Journal of Cancer Care
European Journal of Cancer Care 医学-康复医学
CiteScore
4.00
自引率
4.80%
发文量
213
审稿时长
3 months
期刊介绍: The European Journal of Cancer Care aims to encourage comprehensive, multiprofessional cancer care across Europe and internationally. It publishes original research reports, literature reviews, guest editorials, letters to the Editor and special features on current issues affecting the care of cancer patients. The Editor welcomes contributions which result from team working or collaboration between different health and social care providers, service users, patient groups and the voluntary sector in the areas of: - Primary, secondary and tertiary care for cancer patients - Multidisciplinary and service-user involvement in cancer care - Rehabilitation, supportive, palliative and end of life care for cancer patients - Policy, service development and healthcare evaluation in cancer care - Psychosocial interventions for patients and family members - International perspectives on cancer care
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信